AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00760981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: The single cohort for this study will receive 2 dose levels of imatinib, 200 mg orally daily followed by 400 mg orally daily.
Study NCT01974609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narcotic
Description: Hydrocodone 5mg + acetaminophen 325 mg
Study NCT01974609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-narcotic
Description: ibuprofen 600mg + acetaminophen 325 mg
Study NCT03221218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced screening-informed follow up letter
Description: Family Physicians will be sent a letter that includes their screening test results and associated symptom-specific recommendations from the Ontario Neurotrauma Foundation clinical practice guidelines.
Study NCT01311700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectable (i.v.) metoprolol tartrate (up to 15 mg).
Description: Patients are randomized to active intervention (early metoprolol initiation strategy) or no treatment (delayed metoprolol initiation strategy).~Patients randomized to early metoprolol initiation strategy receive up to three 5mg i.v. dosages (2 minutes apart) before reperfusion.~Patients randomized to delayed metoprolol initiation strategy receive no active treatment before reperfusion.~Patients in both groups receive oral metoprolol tartrate treatment (25-100mg/12h), starting 12-24 hr post-reperfusion.
Study NCT02685709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide capsules
Study NCT02685709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide capsules
Study NCT03543085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GiMer Medical MN 1000 External Stimulator
Description: Trial stimulator (GiMer Medical Model 1000 External Stimulator) to generate pulsed ultrahigh frequency (>200KHz) electrical stimulation, delivered via lead in epidural space, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
Study NCT01682850 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Pulmonary Rehabilitation
Description: Participants in this group will under go 10 sessions of mindfulness based pulmonary rehabilitation prior to surgery. Each session is about 2 hours long and consists of upper /lower extremity training, breathing exercises, and education.
Study NCT01682850 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Study NCT03295214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen given for pain relief
Study NCT03336502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Posaconazole 18 mg/mL IV solution; posaconazole 40 mg/mL oral suspension
Study NCT02935309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Pre-surgery Lenvatinib, days 1 - 5. Dose Escalation Levels: 1.) 10 mg by mouth (PO) daily (QD); 2.) 14 mg PO QD; 3.) 20 mg PO QD; 4.) 24 PO QD.
Study NCT02935309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Pre-surgery Capecitabine, 850 mg/m\^2, twice a day (BID) on days 1-5 for 5½ -6 weeks.
Study NCT02935309 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Radiation Therapy (XRT)
Description: Pre-surgery RT: Participants will receive 6 weeks of radiation therapy. The radiation sessions will be daily, Monday through Friday, except for holidays.
Study NCT03869255 — intervention group
Intervention type: PROCEDURE
Intervention: Nasal swab
Description: In hospitalized patiens, a nasal swab will be performed within the first 48 hours and on the 7th day. In community patient, only one swab will be performed
Study NCT00216970 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: Alteration in nutritional support
Description: The subject is randomized into one of two groups - One receives TPN that does not have arginine, proline or glutamate. The other will receive TPN with extra glutamine. The subject takes part in 3 tracer studies while in the hospital. For each tracer study, the subject will receive a different randomly assigned diet. Blood and air are sampled and the patient receives a stable isotope after which the tests are repeated.
Study NCT02952183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAMS I
Description: After general anesthesia, pressure sensor of PAMS I is placed into bladder, vagina and rectum. Then pressure change is monitored during performing pelvic autonomic nerve dissection.~Both PAMS I and IOM will be used for monitoring.
Study NCT02094144 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brisk walking program
Description: The intervention consists on achieve 40 minutes of brisk walking 3d/wk for 6 months (two supervised sessions and one session performed one their own per week with a detailed program). The intensity of the program is adapted to the heart rate work and gradually increases over the 6-month program
Study NCT02094144 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: physical activity habit
Description: The Intervention consists on maintain the lifestyle and especially their physical activity habits during 6 months
Study NCT03719157 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral ESP Block
Description: USG guided ESP block will perform unilateral with Bupivacaine and Lidocain mixture
Study NCT03719157 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral OSTAP Block
Description: USG guided OSTAP block will perform unilateral with Bupivacaine and Lidocain mixture
Study NCT03719157 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection of Local Anesthetic to Trocar Insertion
Description: Bupivacaine infiltration will be performed at the end of the surgical procedure to trocar insertion sites.
Study NCT01680198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02386189 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Care Coordination Training
Description: Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.
Study NCT03719157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous patient controlled analgesia
Description: All patients were followed using a standardized postoperative analgesia protocol which includes tramadol PCA. Tramadol at a concentration of 5 mg/mL is included in our PCA protocol (total volume 100 mL.) PCAs were set to no basal infusion and 10 mg bolus doses with a 20 min lock time.
Study NCT03719157 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: intravenous patient controlled analgesia
Description: All patients were followed using a standardized postoperative analgesia protocol which includes tramadol PCA. Tramadol at a concentration of 5 mg/mL is included in our PCA protocol (total volume 100 mL.) PCAs were set to no basal infusion and 10 mg bolus doses with a 20 min lock time.
Study NCT03237468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck strengthening exercise to prevent concussion
Description: Neck strengthening exercise to prevent concussion in student athletes.
Study NCT00535925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SoC therapy
Description: the patients have to be treated according the standard good medical practice by any center
Study NCT00535925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irbesartan
Description: Therapy for hypertension:~- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die
Study NCT00535925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramipril
Description: Therapy for hypertension:~- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die
Study NCT00535925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide
Description: Therapy for hypertension~- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine \<2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)
Study NCT00535925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide
Description: Therapy for hypertension~- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine \<2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)
Study NCT00535925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine
Description: Therapy for hypertension~- Step 3: amlodipine up to 10 mg/die
Study NCT00535925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atenolol
Description: Therapy for hypertension~- Step 4: atenolol up to 100 mg/die
Study NCT00535925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxazosin
Description: Therapy for hypertension~- Step 5: doxazosin up to 4 mg/die
Study NCT00535925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: Therapy for hypertension~- Step 6: clonidine
Study NCT00535925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin
Description: Therapy for Hyperglycaemia (to achieve HbA1c \<7):~- insulin
Study NCT00535925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: Therapy for hypercholesterolemia:~- for reducing LDL cholesterol \< 100 mg/dl: simvastatin up to 80 mg/die
Study NCT00535925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fibrate
Description: Therapy for hypertriglyceridemia~- for reducing triglycerides \< 150 mg/dl and/or increasing HDL cholesterol > 40-50 mg/dl: a fibrate
Study NCT00535925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin
Description: Treatment of anaemia:~- erythropoietin
Study NCT00535925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: Antiplatelet therapy (in all patients without contraindications):~- aspirin up to 160 mg/die
Study NCT02906072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low fat plant-based diet
Description: Conventional low fat plant-based meals three times daily. Plant-based meal replacements: Herbalife European Free From vanilla two times daily. Portion sizes and intake is unrestricted.
Study NCT02906072 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lectures on health effects of a low fat plant-based diet.
Description: Participants attend the lectures on health effects of a low fat plant-based diet.
Study NCT02906072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lectures on health effects of a low fat plant-based diet.
Description: Participants attend the lectures on health effects of a low fat plant-based diet.
Study NCT00476580 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questions to collect health information specific to Sri Lankans.
Study NCT02240043 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: growth hormone secretion
Description: The glucagon stimulation test (GST) was performed by intramuscular injection of 1 mg of glucagon (Glucagen® Hypokit, Novo Nordisk A/S, Denmark). The blood samples were collected at baseline and after 90 minutes, 120 minutes, 150 minutes and 180 minutes of glucagon injection for GH and cortisol measurements. The subjects were recumbent during the test, and a cannula was maintained in a vein in the arm or forearm with a saline solution slowly infused to avoid multiple punctures.
Study NCT03357393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam is givenas sedation to the Control arm.
Study NCT03357393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol-Lipuro
Description: Propofol is given as sedation to both intervention arms.
Study NCT03357393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine-scopolamine
Description: Given as premedication for the Control arm and one of the interventions arms.
Study NCT03357393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine-scopolamine
Description: Given as premedication for the Control arm and one of the interventions arms.
Study NCT03357393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: Given as premedication for one of the intervention arms..
Study NCT03311048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal swab
Description: Nasal swab was collect to upper airways inflammation evaluation.
Study NCT03311048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
Study NCT01228903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Xanthine oxidase inhibitor- effective at lowering uric acid levels.
Study NCT01228903 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets with no active ingredient
Study NCT02934438 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Neo40
Study NCT02934438 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03390738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenous nivolumab 240mg every 2 weeks until radiologically-documented disease progression, unacceptable toxicity as judged by investigators or patient withdrawal
Study NCT00282841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: single intravenous administration of maximum 1.5 milliliter ultrasound contrast agent (Definity), followed by maximum 15 minutes transcranial insonation using diagnostic ultrasound.
Study NCT03779022 — intervention group
Intervention type: GENETIC
Intervention: microRNA
Description: The level of microRNA in plasma will be detected by TaqMan in screening phase and by quantitative Real-time PCR (qRT-PCR) in validation phase.
Study NCT01798576 — intervention group
Intervention type: DRUG
Intervention: Pegylated Interferon alfa-2a
Description: Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.
Study NCT01798576 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.
Study NCT00864266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Standard cisplatin-based chemotherapy in agreement with the ELCWP guidelines (available on the website www.elcwp.org)
Study NCT01931059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: We gave oral liquid of risperidone one time 1-2 mg depending on subject's weight.
Study NCT01931059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: We gave oral liquid without active risperidone (pt and provider were both double blinded)
Study NCT02647073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Canary 01 Mobile Vital Signs Monitoring Device
Description: The prototype has several main components, including several commercially available sensors to measure heart rate, respiration, and motion data, an enclosed case containing circuitry for processing and transmitting data, and a mobile phone/system interface to store and transmit data.
Study NCT02427347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into gallbladder-meridian(GB)26 about 25-65mm deep by an angle of 15°, following the path of Dai Meridian (towards medial and downside) . The other acupoints are inserted with needles of 0.25-0.3mm in diameter and 25-40mm in length approximately 10-30mm deep, with an angle of 90°. Electro-acupuncture is applied to both sides of GB26 and stomach-meridian(ST)25: cathode is connected to GB26; anode to ST25. Dense-disperse wave pattern and a wave frequency of 2/100 Hertz is chosen. The intensity of the electro-acupuncture is adjusted on average 4-8 milliampere. The needles are subsequently retained for 20min. The results of the study are based on 8 weeks, each week consisting of 3 sessions.
Study NCT02427347 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Healthy education
Description: Healthy knowledge lectures and issuing brochures are given. Education of patients for conditioning and changing bad habits, diet, quit smoking, limit alcohol consumption, salt restriction, appropriate increase in physical activity.
Study NCT02427347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy education
Description: Healthy knowledge lectures and issuing brochures are given. Education of patients for conditioning and changing bad habits, diet, quit smoking, limit alcohol consumption, salt restriction, appropriate increase in physical activity.
Study NCT03519542 — intervention group
Intervention type: DRUG
Intervention: Sunitinib
Description: Identify prognosis and predictive biomarkers of response to sunitinib and pazopanib as first line therapy in avanced or metastatic renal cell carcinoma.
Study NCT01507064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: tablets 200mg dosage: 400mg bid duration: 4 weeks
Study NCT01507064 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser ablation (LA)
Description: For LA, we use a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the tumor through four 21-gauge needles. The tips of the needles will be positioned at a distance of 15mm from each other.~When, after LA treatments, CT or MRI findings show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used.
Study NCT01507064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser ablation (LA)
Description: For LA, we use a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the tumor through four 21-gauge needles. The tips of the needles will be positioned at a distance of 15mm from each other.~When, after LA treatments, CT or MRI findings show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used.
Study NCT01522846 — intervention group
Intervention type: DRUG
Intervention: Heparin
Description: Heparinized flush solution contained heparin concentration of 2 unit/ml and continuous flow of the flush solution was 5 ml/h at 300 mmHg.
Study NCT01966549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 6785
Description: CNTO 6785 (6 mg/kg) will be administered by intravenous (into a vein) infusion on Weeks 0, 2, 4, 8 and 12. Participants who weigh more than 100 kg will receive a dose of 600 mg of CNTO 6785.
Study NCT01966549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile, 5 percent dextrose will be used as the placebo in this study. Placebo will be administered by intravenous infusion on Weeks 0, 2, 4, 8 and 12.
Study NCT02000947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).
Study NCT02000947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
Study NCT02000947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
Study NCT02629562 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B12019 and Neulasta
Description: GCSF, Growth Colony Stimulating Factor
Study NCT01946815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Lipitor dose titration will be followed by the result of LDL lab test until it meets the target level of LDL. IVUS(optional) and FFR during follow up CAG in 12 months will be measured to evaluate the effect of lipitor.
Study NCT02714166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen lotion SPF (Sun Protection Factor) 50 (BAY987521)
Description: Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
Study NCT02714166 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ophthalmic Ointment
Description: Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
Study NCT03436615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB206 4%
Description: Twice daily
Study NCT03436615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB206 8%
Description: Twice daily
Study NCT01790243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutonix Drug Coated Balloon
Description: Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.
Study NCT01790243 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PTA Balloon
Description: Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.